Fulcrum Therapeutics, Inc. Common Stock
$3.79
$0.01 (+0.26%)
$3.77Day Range$3.81
Key Statistics
Market Cap
$289.17M
Shares Outstanding
76.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 18, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$3.80
Day High
$3.81
Day Low
$3.77
Volume
1.13M
VWAP
$3.79
Prev Close
$3.78
Transactions
--
Acc. Volume
--
About Fulcrum Therapeutics, Inc. Common Stock
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
PHARMACEUTICAL PREPARATIONSSIC 283455 employees26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139617-651-8851IPO Jul 18, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001680581
- Composite FIGI
- BBG00DDY1RK9
- Share Class FIGI
- BBG00DDY1RM7
- Ticker Root
- FULC
- SIC Code
- 2834
About Fulcrum Therapeutics, Inc. Common Stock (FULC) Stock
Fulcrum Therapeutics, Inc. Common Stock (FULC) closed the 2026-09-16 session at $3.79, up 0.26% versus the previous close (+0.01). The stock opened at $3.80 and traded between $3.77 and $3.81 during that session. Session trading volume was 1.1M shares. The volume-weighted average price (VWAP) is $3.79.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Fulcrum Therapeutics, Inc. Common Stock has a market capitalization of $289.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. FULC is listed on the XNAS exchange. The company employs approximately 55 people. Fulcrum Therapeutics, Inc. Common Stock is headquartered in CAMBRIDGE, MA. The recorded listing date is 2019-07-18.
On this page you can find market FULC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.